Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the pricing of its previously announced public offering of 8.3 million shares of its common stock at a price to the public of $7.50 per share. The offering is expected to settle and close on September 14, 2010, subject to customary closing conditions. Barclays Capital Inc. is the sole book-running manager of the offering and Halozyme has granted the underwriter a thirty (30) day option to purchase up to 1,245,000 additional shares. Halozyme intends to use the net proceeds from the offering for general corporate purposes and to support further research and development of its product candidates.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained after it is filed from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; [email protected] (phone: 888-603-5847).
Gut health and diet: Keys to treating acne, alopecia, and dermatitis